UBC Medical Indonesia Tbk. vs Summarecon Agung Tbk. — how do they compare? UBC Medical Indonesia Tbk. trades at Rp148 (market cap 576.7B, 3.48M 24h volume), while Summarecon Agung Tbk. trades at Rp298 (market cap 4.79T, 12.25M 24h volume). The key difference: Summarecon Agung Tbk. is far larger — about 8.3× UBC Medical Indonesia Tbk.'s market cap, and Summarecon Agung Tbk. is more actively traded (12.25M versus 3.48M). Which is the better fit depends on your goals.
| LABS | SMRA | |
|---|---|---|
Market Cap | 576.7B | 4.79T |
Volume | 3.48M | 12.25M |
Lot | 34.82K | 122.47K |
Turnover | 522.79M | 3.62B |
Average Price | 150.13 | 295.63 |
Value | 522.79M | 3.62B |
Indicative Equilibrium Price | 148 | 298 |
Indicative Equilibrium Volume | 350 | 2.11K |
Trailing returns across standard periods
Latest headlines on both assets
PT UBC Medical Indonesia (the Company) was established under the framework of Law of the Republic of Indonesia No. 20 year 1994 concerning the Foreign Capital Investment, as amended by Law No. 25 year 2007 concerning the Capital Investment based on Notarial Deed No. 01 dated 4 June 2014 of Novita Puspitarini, S.H., Notary in Jakarta. The Company started its commercial activities in October 2014. The parent entity as well as the ultimate parent entity of the Company is PT Optel Investama Mulia.
Read more on LABS →PT Summarecon Agung Tbk (the Company) was established within the framework of the Domestic Capital Investment Law based on notarial deed No. 308 dated November 26, 1975 of Ridwan Suselo, S.H. PT. Summarecon Agung Tbk is one of the nation`s leading township developers. Entering its twenty-forth year, the original 10-hectare landbank it started with has turned into a vibrant, 500 hectare township in North Jakarta where commercial vivacity peacefully coexists with its houses numbering in the tens of thousands.
Read more on SMRA →